Labeling Rule Could Strike Implied Indications, GSK Exec Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The "Highlights" section of the revised labeling will be the biggest challenge due to its size restriction, GSK Strategic Product Labeling Group Director Hardy says. She recommends that firms prepare to rework their labels but cautioned against investing a lot of time anticipating a rule change that might not happen.
You may also be interested in...
FDA Physician Labeling Rule Withdrawn From OMB
Final rule has drawn opposition from industry, especially the addition of a "highlights" section. FDA is proposing staggered implementation to lower the costs of the labeling redesign. Rule would also affect DTC ads. Office of Management & Budget received the reg in January.
FDA Physician Labeling Rule Withdrawn From OMB
Final rule has drawn opposition from industry, especially the addition of a "highlights" section. FDA is proposing staggered implementation to lower the costs of the labeling redesign. Rule would also affect DTC ads. Office of Management & Budget received the reg in January.
FDA Drug Label Rule Is “In Its Final Stages,” Crawford Says
Acting Commissioner Crawford has given FDA staff “one more week” to work out final language of the revised drug labeling format rule.